Popular search terms:
Report An Undesirable Effect
Contact information for reporting an Undesirable Effect relating to one of our treatments.
View Contact Information on CSL.comSearch Results
103 results found-
Our Australian offices are in Melbourne, Victoria, Australia
https://www.cslbehring.com.au/contact-us -
Social Media Community Guidelines for CSL Behring Corporate Channels
https://www.cslbehring.com.au/social-guidelines -
CSL is committed to protecting the privacy of all the individuals it deals with. This document sets out our policies on handling personal information (including health information).
https://www.cslbehring.com.au/privacy -
Our partnering approach is to structure deals that leverage the value of CSL Behring’s world-class R&D, commercial and manufacturing operations.
https://www.cslbehring.com.au/partnering -
Learn more about the CSL Behring Broadmeadows Community Grant.
https://www.cslbehring.com.au/our-company/the-csl-behring-commitment/csl-behring-community-grant/how-to-apply -
CSL Behring is committed to advancing scientific knowledge, fostering excellence, and supporting future medical researchers.
https://www.cslbehring.com.au/research-and-development/awards-and-grants/professor-heimburger-award -
Patients should be informed about first symptoms of thromboembolic events including shortness of breath, pain and swelling of a limb, focal neurological deficits and chest pain and should be advised to contact their physician immediately upon onset of symptoms.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/normal-immunoglobulin-au-pi-1000.pdf -
Patients should be informed about first symptoms of thromboembolic events including shortness of breath, pain and swelling of a limb, focal neurological deficits and chest pain and should be advised to contact their physician immediately upon onset of symptoms.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/normal-immunoglobulin-nz-ds-1200.pdf